The dynamic ingredient in BESPONSA is inotuzumab ozogamicin. This belongs to a group of drugs or medicines that objective cancer cells. These drugs are called antineoplastic agents.
BESPONSA is utilized to treat adults with intense lymphoblastic leukaemia. Acute lymphoblastic leukaemia is a cancer of blood where you have too many white cells.
BESPONSA is planned for the treatment of acute lymphoblastic leukaemia for adult patients who have recently attempted other medicines and for whom those medications have failed.
BESPONSA acts by joining to cells with a protein called CD22. Lymphoblastic leukaemia cells have this protein. Once attached to the lymphoblastic leukaemia cells, the drug delivers a substance into the cells that interfere with the cells’ DNA and eventually kills them.
- Pain in the abdomen
- Mouth inflammation